Received Mar 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | W011264 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | W026150 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | W011264 | — |
No symptoms reported; Customer called to report that 2 years ago a female patient in her 20s received her 2nd and 3rd dose of GARDASIL 9 within 10 weeks of each other. No symptoms reported. See related request case 02772685. Patient's first dose received on 20DEC2022; Information has been received from Business Partner/CRO on 18-Mar-2025. This spontaneous report was received from a/an Pharmacist and refers to a(n) Adult female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 30-Jun-2023, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (lot #W026150, expiration date: 20-Oct-2024), dose number 3, 0.5 mL. On 20-Dec-2022, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (lot #W011264, expiration date: 05-Sep-2024), dose number 1, 0.5 mL. On 13-Apr-2023, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (lot #W011264, expiration date: 05-Sep-2024), dose number 2, 0.5 mL. On an unknown date, the patient started therapy with unknown dosage. On an unknown date, the patient started therapy with unknown dosage. On an unknown date, the patient started therapy with unknown dosage. The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant for the treatment of prophylaxis. The patient started therapy with for the treatment of prophylaxis. The patient started therapy with for the treatment of prophylaxis. The patient started therapy with for the treatment of prophylaxis. The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant for the treatment of prophylaxis. The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant for the treatment of prophylaxis. On 30-Jun-2023, the patient experienced Customer called to report that 2 years ago a female patient in her 20s received her 2nd and 3rd dose of GARDASIL 9 within 10 weeks of each other. No symptoms reported. See related request case 02772685. Patient's first dose received on 20DEC2022. On an unknown date, the patient experienced No symptoms reported. At the reporting time, the outcome of Customer called to report that 2 years ago a female patient in her 20s received her 2nd and 3rd dose of GARDASIL 9 within 10 weeks of each other. No symptoms reported. See related request case 02772685. Patient's first dose received on 20DEC2022 and No symptoms reported was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant. nHuman Papillomavirus 9-valent Vaccine, Recombinant and Human Papillomavirus 9-valent Vaccine, Recombinant was reported as not applicable.